SINGLE DOMAIN ANTIBODIES AND BIOENGINEERING DRUGS ON THEIR BASIS: NEW OPPORTUNITIES FOR DIAGNOSTICS AND THERAPY

Almost 20 years ago, a unique class of antibodies devoid of L chains was discovered in Camelidae blood serum. Only one variable domain is responsible for antigen recognition in these unusual antibodies. A recombinant protein, which is analogue to such antigen-recognizing variable domain was called t...

Full description

Saved in:
Bibliographic Details
Published in:Medit͡s︡inskai͡a︡ immunologii͡a 2016-01, Vol.18 (6), p.505
Main Authors: Gorshkova, E N, Vasilenko, E A, Tillib, S V, Astrakhantseva, I V
Format: Article
Language:Russian
Subjects:
Antibodies
Antigens
Autoimmune diseases
Bioengineering
Cancer
Immunoglobulins
Infectious diseases
Nanobodies
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Almost 20 years ago, a unique class of antibodies devoid of L chains was discovered in Camelidae blood serum. Only one variable domain is responsible for antigen recognition in these unusual antibodies. A recombinant protein, which is analogue to such antigen-recognizing variable domain was called the single domain antibody (sdAb), “nanobody” or “nanoantibody”. The single-domain antibodies and their derivatives have been widely used in the field of biology, toxicology and medicine offering new opportunities for diagnosis and treatment of cancer, autoimmune diseases, infectious diseases, and for toxin neutralization. This review focuses on latest researches in the field and concerns some prospectives for creation of nanoantibody-based diagnostic and therapeutic drugs.
ISSN:1563-0625
2313-741X
DOI:10.15789/1563-0625-2016-6-505-520